Julie Dexter
Human Resources Officer bij OLEMA PHARMACEUTICALS, INC.
Oorsprong van het eerstegraads netwerk van Julie Dexter
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Julie Dexter via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| GILEAD SCIENCES, INC. | Biotechnology | Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Kosan Biosciences, Inc.
 Kosan Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Roche Holdings, Inc.
 Roche Holdings, Inc. Financial ConglomeratesFinance Roche Holdings, Inc. operates as a holding company, which engages in the manufacture and distribution of pharmaceutical and vitamin products. It also provides financial services to other members of the RHI Group and to refinance on the bond or loan markets. The company was founded in 1987 and is headquartered in San Francisco, CA. | Financial Conglomerates | Chief Tech/Sci/R&D Officer | |
| PTC THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
Epiphany Biosciences, Inc.
 Epiphany Biosciences, Inc. Medical SpecialtiesHealth Technology Epiphany Biosciences, Inc. develops therapeutic products and diagnostic technologies that treat and prevent the spread of pathogenic viruses. The firm develops therapeutics to prevent spread of varicella zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis C virus (HCV). The company was founded by David C Myles, Robert Charles Gallo, Harold E Selick and Frederick Volinsky in 2001 and is headquartered in San Francisco, CA. | Medical Specialties | Founder | |
Knopp Biosciences LLC
 Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Pharmaceuticals: Major | Director/Board Member | |
| TURG POIN | Pharmaceuticals: Major | Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| Dartmouth College | College/University | Undergraduate Degree | |
| KARO PHARMA AB (PUBL) | Pharmaceuticals: Major | Director/Board Member | |
National Bank Financial, Inc.
 National Bank Financial, Inc. Investment ManagersFinance National Bank Financial, Inc. (NBF) is a Canadian mutual fund manager headquartered in Montréal, Quebec. The firm was founded in 1902 and is a direct subsidiary of National Bank Acquisition Holding, Inc., ultimately owned by National Bank of Canada (TSX: NA). NBF is an integrated firm that combines retail advisory and brokerage services with institutional brokerage, investment banking, corporate finance and securities clearing services for third parties. | Investment Managers | Corporate Officer/Principal | |
| University of California, Los Angeles | College/University | Corporate Officer/Principal | |
| Queen's University | College/University | Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree | |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Howard Hughes Medical Institute, Inc. engages in the provision of biomedical research services and science education programs. It funds grants to both institutions and individuals in support of a wide range of science and research-related initiatives, including precollege and undergraduate science education, pre- and post-doctoral research fellowships, and international research activities. The company was founded by Howard R. Hughes in 1953 and is headquartered in Chevy Chase, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| Occidental College | College/University | Undergraduate Degree | |
| University of Wisconsin | College/University | Masters Business Admin Undergraduate Degree | |
| University of California, Berkeley | College/University | Doctorate Degree Undergraduate Degree | |
| University of Iowa | College/University | Doctorate Degree | |
| The University of California, San Francisco | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| California Polytechnic State University (San Luis Obispo) | College/University | Undergraduate Degree Undergraduate Degree | |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Medical/Nursing Services | President | |
| KITE PHARMA INC | Biotechnology | Director/Board Member Director of Finance/CFO | |
| Stanford University School of Medicine | College/University | Corporate Officer/Principal Doctorate Degree | |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Biotechnology | Director/Board Member Director/Board Member | |
| ALX ONCOLOGY HOLDINGS INC. | Biotechnology | Director/Board Member Director/Board Member | |
EQRx International, Inc.
 EQRx International, Inc. Pharmaceuticals: MajorHealth Technology EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Founder | |
Credit Suisse (Australia) Ltd.
 Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Credit Suisse (Australia) Ltd. (Credit Suisse Australia) is a broker/dealer firm headquartered in Sydney, Australia. The firm was founded in 1999 and is a subsidiary of Credit Suisse AG, which is owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Australia offers global securities sales, trading and execution, prime brokerage, underwriting, and comprehensive investment research for corporate and institutional investors. | Investment Banks/Brokers | Corporate Officer/Principal | |
| Richard Ivey School of Business | College/University | Masters Business Admin | |
| REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
Cellarity Inc.
 Cellarity Inc. BiotechnologyHealth Technology Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
| EQRX, INC. | Pharmaceuticals: Major | Founder | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member | |
| MODERNA, INC. | Biotechnology | Director/Board Member | |
| AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
| CENTURY THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
The Webb School of California
 The Webb School of California Other Consumer ServicesConsumer Services The Webb School of California was founded in 1880 and is based in Claremont, CA. The school offers a college preparatory boarding and day high school experience with an unbounded curriculum and cultural and environmental assets. | Other Consumer Services | Director/Board Member | |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member | |
Altrubio, Inc.
 Altrubio, Inc. Internet RetailRetail Trade Altrubio, Inc. is a clinical-stage biotechnology company based in Redwood City, CA. The company specializes in developing novel therapies leveraging immune checkpoint agonism to enhance the function of natural pathways to downregulate an overactivated immune system. Altrubio's pipeline includes two clinical stage product candidates: neihulizumab, an immune checkpoint agonist antibody targeting PSGl-1/CD162 that depletes unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases, and ABGN-107, an antibody-drug conjugate employing a unique enzyme cleavable hydrophilic self-immolative linker and targeting a gastrointestinal tumor antigen. The company was founded in 2000, and the CEO is Judy Chou. | Internet Retail | Director/Board Member | |
| FOUNDATION MEDICINE INC | Medical/Nursing Services | Director/Board Member | |
| Temple University School of Medicine | College/University | Doctorate Degree | |
| SCIENCE 37 HOLDINGS, INC. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 36 |
| Verenigd Koninkrijk | 6 |
| Canada | 4 |
| Zweden | 2 |
| Australië | 2 |
Sectoraal
| Health Technology | 24 |
| Consumer Services | 15 |
| Finance | 4 |
| Health Services | 3 |
| Miscellaneous | 2 |
Operationeel
| Director/Board Member | 79 |
| Corporate Officer/Principal | 42 |
| Independent Dir/Board Member | 36 |
| Undergraduate Degree | 18 |
| Director of Finance/CFO | 11 |
Sterkste connecties
| Insiders | |
|---|---|
| Ian Clark | 35 |
| Andy Rappaport | 27 |
| Cynthia Butitta | 16 |
| Sandra Horning | 14 |
| Graham Walmsley | 13 |
| J. Garland | 13 |
| Shane Kovacs | 11 |
| Sean Bohen | 9 |
| David Myles | 9 |
| Gorjan Hrustanovic | 7 |
| Yi Larson | 7 |
| Peter Kushner | 6 |
| Naseem Zojwalla | 6 |
| Cyrus Harmon | 4 |
| Kamesh Kuchimanchi | 4 |
- Beurs
- Insiders
- Julie Dexter
- Bedrijfsconnecties
